8-K

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

        Date of Report (Date of earliest event reported) April 12, 2004

                                PhotoMedex, Inc.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

          Delaware                        0-11635                59-2858100
- ----------------------------         ----------------        -------------------
(State or other jurisdiction         (Commission File           (IRS Employer
     of incorporation)                    Number)            Identification No.)

147 Keystone Drive, Montgomeryville, PA                             18936
- ----------------------------------------                         ----------
(Address of principal executive offices)                         (Zip Code)

        Registrant's telephone number, including area code 215.619.3600

          ------------------------------------------------------------
          (Former name or former address if changed since last report)

================================================================================




Item 9      Regulation FD Disclosure on April 12, 2004, the Registrant announced
- ------      that Regence Group, a private health plan, had approved for
            reimbursement procedures using the XTRAC(R)excimer laser to treat
            psoriasis.

            The Information contained herein and in the accompanying exhibit
            shall not be incorporated by reference into any filing of the
            Registrant, whether made before or after the date hereof, regardless
            of any general incorporation language in such filing, unless
            expressly incorporated by specific reference to such filing. The
            information in this report, including the exhibit hereto, shall not
            be deemed to be "filed" for purposes of Section 16 of the Securities
            Exchange Act of 1934, as amended, or otherwise subject to the
            liabilities of that section or Sections 11 and 12 (a) (2) of the
            Securities Act of 1933, as amended.


                                       2



                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                     PhotoMedex, Inc.

                      Date: April 15, 2004           By: /s/ Dennis M. McGrath
                                                         -----------------------
                                                         Chief Financial Officer


                                       3




                                  EXHIBIT INDEX


Exhibit No.       Subject Matter       Press release of PhotoMedex, Inc.
99.1

PhotoMedex Press Release dated April 12, 2004, reporting the announcement that
Regence Group Adopts Reimbursement for PhotoMedex XTRAC(R)

EX-99.1

                                                                    Exhibit 99.1

         The Regence Group Adopts Reimbursement for PhotoMedex XTRAC(R)


    MONTGOMERYVILLE, Pa. and CARLSBAD, Calif., April 12 /PRNewswire-FirstCall/
- -- PhotoMedex (Nasdaq: PHMD) today announced that The Regence Group, with
nearly 3 million medical members and over 44,000 Blue Cross/Blue Shield
providers has adopted a medical policy approving payment for medically
necessary treatment of mild to moderate psoriasis using the PhotoMedex
XTRAC(R) laser system.

    Jeff O'Donnell, PhotoMedex' CEO said, "We are pleased with the continued
progress we are making on the insurance reimbursement front.  We have always
believed in the clinical superiority of the XTRAC(R).  Regence's decision not
only affirms that view, but further demonstrates that our XTRAC(R) therapy
cost-effectively provides those outcomes."

    The Regence Group includes Blue Shield of Washington, Blue Cross Blue
Shield of Oregon, Blue Cross Blue Shield of Utah, and Blue Shield of Idaho.
The medical policy covering the XTRAC(R) can be found at
http://www.regence.com/trgmedpol/medicine/med98.html.


    About PhotoMedex:

    PhotoMedex provides contract medical procedures to hospitals,
surgi-centers and doctors' offices, offering a wide range of products and
services across multiple specialty areas, including dermatology, urology,
gynecology, orthopedics, and other surgical specialties.  The company is a
leader in the development, manufacturing and marketing of medical laser
products and services.


    Some portions of this release, particularly those describing PhotoMedex'
strategies, operating expense reductions and business plans, will contain
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1993, as amended and Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. While PhotoMedex is
working to achieve those goals, actual results could differ materially from
those projected in the forward-looking statements as a result of a number of
factors, including difficulties in marketing its products and services, need
for capital, competition from other companies and other factors, any of which
could have an adverse effect on the business plans of PhotoMedex, its
reputation in the industry or its results.  In light of significant
uncertainties inherent in forward-looking statements included herein and in
the conference call, the inclusion of such information in the release call
should not be regarded as a representation by PhotoMedex or its subsidiaries
that the forward looking statements will be achieved.


    For further information, please contact:  investors, Matt Clawson of Allen
& Caron, +1-949-474-4300, matt@allencaron.com, for PhotoMedex, Inc.; or Dennis
McGrath, CFO of PhotoMedex, Inc., +1-215-619-3287, info@photomedex.com



SOURCE  PhotoMedex, Inc.
    -0-                             04/12/2004
    /CONTACT:  investors, Matt Clawson of Allen & Caron, +1-949-474-4300,
matt@allencaron.com, for PhotoMedex, Inc.; Dennis McGrath, CFO of PhotoMedex,
Inc., +1-215-619-3287, info@photomedex.com/
    /Web site:  http://www.photomedex.com/
    (PHMD)

CO:  Regence Group; PhotoMedex, Inc.
ST:  California
IN:  MTC HEA BIO
SU:  PDT